Effect of Vitamin D3 Supplementations on FEV1 and FVC in Patients with Non-small cell Lung Cancer

Abstract

The current study was conducted at the Middle Euphrates Center for tumors from December 2015 to July 2016 on 90 subjects, thirty healthy person were saved as a control group (G1), and the other group with 60 patients with lung cancer (LC) were subdivided into two subgroup (30 / group), group (G2 was not administered and group G3 was administered) with 1000 IU of vitamin D3) cholicalciferol). In the base line of study, vitamin D concentration and some of lung functions like Forced Vital Capacity (FVC), and Forced Expiratory Volume in the First second (FEV1) were measured for all groups. Then group G3 orally administered 1000 IU of  vitamin D3  for 63 days  then  groups of patients (G2 and G3) were exposed intravenous to 3 doses of Cisplatine 75mg/m2 and Gemcitabin  1gm/m2 for 63day (1dose/ 21 day) , then vitamin D and FVC and FEV1were measured. The results of this study showed a significant decrease (P ˂0 .01) in the level of vitamin D (8.6 ± 2.95 and 7.99 ± 3.08) ng / ml in the two groups of patients at the beginning study, vitamin D increased significantly (P ˂ 0.01) to 18.4 ± 5.8 ng / ml in group administrated with vitamin D when compared to the vitamin D in the beginning of study in the same group and group which was not administered with vitamin D.  The values of both FVC and FEV1 maintained their level close to the control values in the vitamin D administrated group (G3). It was being concluded that vitamin D 3 improved lung functions.